Back

From Ageing Biology to Alzheimer's Therapy: Integrating Geroscience, Lifestyle and Pharmacological Strategies.

  • Published In: touchREVIEWS in Neurology, 2025, v. 21, n. 1. P. 5 1 of 3

  • Database: Academic Search Ultimate 2 of 3

  • Authored By: Abdel-Sater, Khaled A. 3 of 3

Abstract

Introduction: The biggest risk factor for Alzheimer's disease (AD) is ageing, contributing to impaired clearance of tau and amyloid-beta proteins, microglial senescence, endoplasmic reticulum (ER) stress, lipid dysregulation and excitotoxicity. This article investigates how ageing speeds up the pathophysiology of AD and evaluates emerging geroscience-based interventions targeting biological ageing mechanisms to delay or prevent cognitive decline. Methods: A narrative review (January 2015 to September 2025) across PubMed, Embase, Cochrane and Google Scholar identified 79 eligible studies on ageing-related mechanisms in AD. Results: Key mechanisms included glymphatic dysfunction, apolipoprotein E (APOE) ε4 pathology, microglial senescence, ER stress, brain- derived neurotrophic factor depletion and excitotoxicity. Interventions ranged from lifestyle strategies (exercise, sleep and diet) to senolytics, epigenetic modulators and stem cell therapies. Conclusion: Targeting ageing mechanisms offers a paradigm shift in AD prevention and treatment; however, multidisciplinary collaboration is essential to translate geroscience into clinical practice. The integration of lifestyle and pharmacological strategies may yield synergistic neuroprotective benefits. Future research should focus on integrated, multimodal interventions that combine lifestyle modification with pharmacological and biological therapies. Tailored approaches -- based on genetic risk profiles (e.g. APOE status), comorbidities and individual ageing trajectories -- may optimize clinical outcomes. To evaluate the long-term safety and effectiveness of innovative treatments such as senolytics, epigenetic modulators and stem cell- based therapies in older populations, extensive longitudinal clinical trials are required. Developments in biological age biomarkers, machine learning and systems biology have the potential to improve risk assessment and therapy customization. [ABSTRACT FROM AUTHOR]

Additional Information

  • Source:touchREVIEWS in Neurology. 2025/01, Vol. 21, Issue 1, p5
  • Document Type:Abstract
  • Subject Area:Complementary and Alternative Medicine
  • Publication Date:2025
  • ISSN:2752-5465
  • DOI:10.17925/USN.2025.21.1.10
  • Accession Number:191029680
  • Copyright Statement:Copyright of touchREVIEWS in Neurology is the property of Touch Medical Media and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.